medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2005, Número 3

<< Anterior Siguiente >>

Ann Hepatol 2005; 4 (3)


Alcoholic intake predisposes to more interface hepatitis in chronic hepatitis C

Gomes de Sá RMF, Costa GLC, Fischer CDA, Strauss E

Idioma: Ingles.
Referencias bibliográficas: 49
Paginas: 176-183
Archivo PDF: 75.56 Kb.


FRAGMENTO

Sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a bloodborne non-A, non-B Hepatitis genome. Science 1989; 44: 359-62.

  2. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35-S46.

  3. Mohsen AH. Trent HCV Study Group. The epidemiology of hepatitis C in a UK health regional population of 5.12 million. GUT 2001; 48: 707-13.

  4. Smith BC, Chapman CE, Burt AD, Toms GL, Bassendine MF. Outcome of post-transfusion hepatitis C: disease severity in blood-component recipients and their implicated donors. QJMed 1997; 90: 587-92.

  5. Tassopoulos NC, Papatheodoridis GV, Katsoulidou A, Delladetsima JK, Sypsa V, Touloumi G, Nikandros M, et al. Factors associated with severity and disease progression in chronic hepatitis C. Hepatogastroenterol 1998; 45: 1678-83.

  6. Pessione F, Degos F, Marcellin P, Duchatelle V, Njapoum C, Martinot-Peignoux M, Degott C, et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 1998; 27(6): 1717-22.

  7. Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis C infections in men and women. Am J Epidemiol 2002; 155(4): 323-31.

  8. Harris HE, Ramsay ME, Andrews N, Eldridge KP on behalf of the HCV National Register Steering Group. Clinical course of hepatitis C virus during the first decade of infection: cohort study. BMJ 2002; 324: 450-3.

  9. Ostapowicz G, Watson KJR, Locarnini SA, Desmond PV. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology 1998; 27(6): 1730-5.

  10. Corrao G, Aricò S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology 1998; 27: 914-9.

  11. Patek AJ, Toth IG, Saunders MG, Castro GAH, Emgel JI. Alcohol and dietary factors in cirrhosis. An epidemiological study of 304 alcoholic patients. Arch Intern Med 1975; 135: 1053-7.

  12. Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus and alcohol. Hepatology 2002; 36(3): 729-36.

  13. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002; 36: S47-S56.

  14. Poynard T, Bedossa P, Opolon P, for the OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-32.

  15. Alter MJ, Marcolis HS, Krawczyski K, Judson FN, Mares A, Alexander WJ, Hu PY, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992; 327: 1899-1905.

  16. Poynard T, Bedossa P. Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J Viral Hepatol 1997; 4(3): 199-208.

  17. Gayotto LCC e Comitê SBP/SBH. Visão histórica e consenso nacional sobre a classificação das hepatites crônicas. Projeto do Clube de Patologia Hepática da Sociedade Brasileira de Patologia aprovado pela Sociedade Brasileira de Hepatologia. GED 2000; 19(3): 137-40.

  18. Poynard T, Ratziu V, Benmanov Y, Martino V, Bedossa P, Opolon P. Fibrosis in patients with chronic hepatitis C: detection and significance. Semin Liver Dis 2000; 20(1): 47-55.

  19. Peters MG, Terrault NA. Alcohol use and hepatitis C. Hepatology 2002; 36: S220-S5.

  20. Wiley TE, McCarthy M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998; 28(8): 805-9.

  21. Maddrey WC. Alcoholic hepatitis: clinicopathologic features and therapy. Semin Liver Dis 1988; 8: 91-102.

  22. Hall P de la M. Alcoholic liver disease. In: Pathology of the liver. Mac Sween RNM, Anthony PP, Portmann BC, Burt AD, reds., 3nd ed. Churchill Livingstone, Edinburgh, 1994.

  23. Strauss E, Nemoto TC, Borges GT, Cunha AA, Freitas GC, Parrado MAR, et al. Chronic alcoholism: evaluation epidemiologic clinic in 300 cases. GED, Gastroenterol Endoscop Dig 1998; 17: S75.

  24. Mendenhall CL, Moritz T, Rouster S, Roselle G, Polito A, Quan S, Dinelle RK. Epidemiology of hepatitis C among veterans with alcoholic liver disease. The VA Cooperative Study Group 275. Am J Gastroenterol 1993; 88: 1022-6.

  25. Verbaan H, Anderson K, Eriksson S. Intravenous drug abuse-the major route of hepatitis C virus transmission among alcohol-dependent individuals? Scand J Gastroenterol 1993; 28: 714-8.

  26. MacGregor RR. Alcohol and immune defense. JAMA 1986; 256: 1474-9.

  27. Cook RT. Alcohol abuse, alcoholism, and damage to the immune system-a review. Alcohol: Clin Exp Res 1998; 22: 1927-42.

  28. Ortiz V, Berenguer M, Rayón JM, Carrasco D, Berenguer J. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 2002; 97(9): 2408-2414.

  29. Fong TL, Kanel GC, Conrad A, Valinluck B, Charboneau F, Adkins RH. Clinical significance of concomitant hepatitis C infection in patients with alcoholic liver disease. Hepatology 1994; 19(3): 554-557.

  30. Mathurin P, Moussalli J, Cadranel JF, Thibault V, Charlotte F, Dumouchel P, Cazier A, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998; 27: 868-72.

  31. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24: 289-93.

  32. Iacono OL, Decastro M, Garcia-Buey L, Garcia-Monzon C, Borque MJ, Sanz P, Garcia-Sanchez A, et al. Epidemiological risk factors and clinic-pathological presentation in chronic hepatitis C. Hepato-Gastroenterol 1998; 45: 1715-1721.

  33. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchisonJ, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34: 730-739.

  34. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 1994; 19: 1513-1520.

  35. Delladetsima JK, Rassidakis G, Tassopoulos NC, Papatheodoridis GV, Smyrnoff T, Vafiadis I. Histopathology of chronic hepatitis C in relation to epidemiological factors. J Hepatol 1996; 24: 27-32.

  36. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, Nolt K, et al. The natural history of hepatitis C virus infection. Host, viral, and environmental factors. JAMA 2000; 284(4): 450-456.

  37. Rodger AJ, Roberts S, Lanigan A, Bowden S, Brown T, Crofts N. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. Hepatology 2000; 32: 582-587.

  38. Ghany MG, Kleiner DE, Alter H, Doo E, Khokar F, Promrat K, Herion D, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003; 124: 97-104.

  39. Silva IS, Ferraz ML, Perez RM, Lanzoni VP, Figueiredo VM, Silva AE. Role of gamma-glutamyl transferase activity in patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol 2004; 19(3): 314-318.

  40. Assy N, Minuk GY. Serum aspartate but not alanine aminotransferase levels help to predict the histological features of chronic hepatitis C viral infections in adults. Am J Gastroenterol 2000; 95(6): 1545-50.

  41. Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 2001; 96(11): 3142-3146.

  42. Streiff MB, Mehta S, Thomas DL. Peripheral blood count abnormalities among patients with hepatitis C in the United States. Hepatology 2002; 35(4): 947-952.

  43. Bauduer F, Marty F, Larrouy M, Ducout L. Immunologic thrombocytopenic purpura as presenting symptom of hepatitis C infection. Am J Hematol 1998; 57(4): 338-340.

  44. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526.

  45. Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, Powell EE. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999; 29: 1215-9.

  46. Scheuer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko GM. The pathology of hepatitis C. Hepatology 1992; 15: 567-571.

  47. Bach N, Thung SN, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis C: a comparative analysis. Hepatology 1992; 15: 572-577.

  48. Lefkowitch JH, Schiff ER, Davis RL, Perrillo RP, Lindsay K, Bodenheimer HC Jr., Balart LA, et al. Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. Gastroenterology 1993; 104: 595-603.

  49. Serfaty L, Poujol-Robert A, Carbonell N, Chazouillères O, Poupon RE, Poupon R. Effect of the interaction between steatosis and alcohol intake on liver fibrosis progression in chronic hepatitis C. Am J Gastroenterol 2002; 97: 1807-1812.




2020     |     www.medigraphic.com